tradingkey.logo

MoonLake climbs after report of Merck buyout talks

ReutersJun 3, 2025 2:26 PM

Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 14.8% to $47.25

Merck MRK.N has held talks to buy MLTX for more than $3 billion, the Financial Times reported on Monday, citing people familiar with the matter

Merck had submitted a nonbinding offer for MoonLake earlier this year - report

MRK's initial approach was rejected, but discussions can potentially resume, the report says

Including session moves, MLTX down 12.6% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI